Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer

Dario Pasalic; Sonia L. Betancourt-Cuellar; Nicolette Taku; Ethan B. Ludmir; Yi Lu; Pamela K. Allen; Chad Tang; Mara B. Antonoff; Clifton D. Fuller; David I. Rosenthal; William H. Morrison; Jack Phan; Adam S. Garden; James W. Welsh; Joe Y. Chang; Zhongxing Liao; Jeremy J. Erasmus; Quynh Nhu Nguyen

doi:10.1002/hed.26117

Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer

Dario Pasalic, Sonia L. Betancourt-Cuellar, Nicolette Taku, Ethan B. Ludmir, Yi Lu, Pamela K. Allen, Chad Tang, Mara B. Antonoff, Clifton D. Fuller, David I. Rosenthal, William H. Morrison, Jack Phan, Adam S. Garden, James W. Welsh, Joe Y. Chang, Zhongxing Liao, Jeremy J. Erasmus, Quynh Nhu Nguyen

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Abstract

Background: Metastatic head and neck cancers (HNCs) predominantly affect the lungs and have a two-year overall survival (OS) of 15% to 50%, if amenable for pulmonary metastasectomy. Methods: Retrospective review of the two-year local control (LC), local-regional control (LRC) within the same lobe, OS, and toxicity rates in consecutive patients with metastatic pulmonary HNC who underwent stereotactic ablative radiotherapy (SABR) January 2007 to May 2018. Results: Evaluated 82 patients with 107 lung lesions, most commonly squamous cell carcinoma (SCC; 64%). Median follow-up was 20 months (range: 9.0-97.6). Systemic therapy administered in 34%. LC, LRC, and OS rates were 94%, 90%, and 62%. Patients with oligometastatic disease had a higher OS than polymetastatic disease, 72% vs 44% (HR = 0.30, 95% CI: 0.14-0.64; P =.008). OS in oligometastatic non-SCC and SCC were 100% and 66% (P =.03). There were no grade ≥3 toxicities. Conclusions: Metastatic pulmonary HNCs after SABR have a two-year OS rate comparable to pulmonary metastasectomy.

Original language	English (US)
Pages (from-to)	1939-1953
Number of pages	15
Journal	Head and Neck
Volume	42
Issue number	8
DOIs	https://doi.org/10.1002/hed.26117
State	Published - Aug 1 2020

Keywords

oligometastasis
pulmonary metastases
pulmonary oligometastases
squamous cell carcinoma
stereotactic body radiotherapy

ASJC Scopus subject areas

Otorhinolaryngology

Access to Document

10.1002/hed.26117

Cite this

Pasalic, D., Betancourt-Cuellar, S. L., Taku, N., Ludmir, E. B., Lu, Y., Allen, P. K., Tang, C., Antonoff, M. B., Fuller, C. D., Rosenthal, D. I., Morrison, W. H., Phan, J., Garden, A. S., Welsh, J. W., Chang, J. Y., Liao, Z., Erasmus, J. J., & Nguyen, Q. N. (2020). Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer. Head and Neck, 42(8), 1939-1953. https://doi.org/10.1002/hed.26117

Pasalic, D, Betancourt-Cuellar, SL , Taku, N , Ludmir, EB, Lu, Y, Allen, PK, Tang, C , Antonoff, MB , Fuller, CD , Rosenthal, DI , Morrison, WH , Phan, J , Garden, AS , Welsh, JW , Chang, JY , Liao, Z , Erasmus, JJ & Nguyen, QN 2020, 'Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer', Head and Neck, vol. 42, no. 8, pp. 1939-1953. https://doi.org/10.1002/hed.26117

@article{69866c1511094cb0b02a1caab70aa246,

title = "Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer",

abstract = "Background: Metastatic head and neck cancers (HNCs) predominantly affect the lungs and have a two-year overall survival (OS) of 15% to 50%, if amenable for pulmonary metastasectomy. Methods: Retrospective review of the two-year local control (LC), local-regional control (LRC) within the same lobe, OS, and toxicity rates in consecutive patients with metastatic pulmonary HNC who underwent stereotactic ablative radiotherapy (SABR) January 2007 to May 2018. Results: Evaluated 82 patients with 107 lung lesions, most commonly squamous cell carcinoma (SCC; 64%). Median follow-up was 20 months (range: 9.0-97.6). Systemic therapy administered in 34%. LC, LRC, and OS rates were 94%, 90%, and 62%. Patients with oligometastatic disease had a higher OS than polymetastatic disease, 72% vs 44% (HR = 0.30, 95% CI: 0.14-0.64; P =.008). OS in oligometastatic non-SCC and SCC were 100% and 66% (P =.03). There were no grade ≥3 toxicities. Conclusions: Metastatic pulmonary HNCs after SABR have a two-year OS rate comparable to pulmonary metastasectomy.",

keywords = "oligometastasis, pulmonary metastases, pulmonary oligometastases, squamous cell carcinoma, stereotactic body radiotherapy",

author = "Dario Pasalic and Betancourt-Cuellar, {Sonia L.} and Nicolette Taku and Ludmir, {Ethan B.} and Yi Lu and Allen, {Pamela K.} and Chad Tang and Antonoff, {Mara B.} and Fuller, {Clifton D.} and Rosenthal, {David I.} and Morrison, {William H.} and Jack Phan and Garden, {Adam S.} and Welsh, {James W.} and Chang, {Joe Y.} and Zhongxing Liao and Erasmus, {Jeremy J.} and Nguyen, {Quynh Nhu}",

note = "Publisher Copyright: {\textcopyright} 2020 Wiley Periodicals, Inc.",

year = "2020",

month = aug,

day = "1",

doi = "10.1002/hed.26117",

language = "English (US)",

volume = "42",

pages = "1939--1953",

journal = "Head and Neck",

issn = "1043-3074",

publisher = "Wiley-Liss Inc.",

number = "8",

}

TY - JOUR

T1 - Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer

AU - Pasalic, Dario

AU - Betancourt-Cuellar, Sonia L.

AU - Taku, Nicolette

AU - Ludmir, Ethan B.

AU - Lu, Yi

AU - Allen, Pamela K.

AU - Tang, Chad

AU - Antonoff, Mara B.

AU - Fuller, Clifton D.

AU - Rosenthal, David I.

AU - Morrison, William H.

AU - Phan, Jack

AU - Garden, Adam S.

AU - Welsh, James W.

AU - Chang, Joe Y.

AU - Liao, Zhongxing

AU - Erasmus, Jeremy J.

AU - Nguyen, Quynh Nhu

PY - 2020/8/1

Y1 - 2020/8/1

N2 - Background: Metastatic head and neck cancers (HNCs) predominantly affect the lungs and have a two-year overall survival (OS) of 15% to 50%, if amenable for pulmonary metastasectomy. Methods: Retrospective review of the two-year local control (LC), local-regional control (LRC) within the same lobe, OS, and toxicity rates in consecutive patients with metastatic pulmonary HNC who underwent stereotactic ablative radiotherapy (SABR) January 2007 to May 2018. Results: Evaluated 82 patients with 107 lung lesions, most commonly squamous cell carcinoma (SCC; 64%). Median follow-up was 20 months (range: 9.0-97.6). Systemic therapy administered in 34%. LC, LRC, and OS rates were 94%, 90%, and 62%. Patients with oligometastatic disease had a higher OS than polymetastatic disease, 72% vs 44% (HR = 0.30, 95% CI: 0.14-0.64; P =.008). OS in oligometastatic non-SCC and SCC were 100% and 66% (P =.03). There were no grade ≥3 toxicities. Conclusions: Metastatic pulmonary HNCs after SABR have a two-year OS rate comparable to pulmonary metastasectomy.

AB - Background: Metastatic head and neck cancers (HNCs) predominantly affect the lungs and have a two-year overall survival (OS) of 15% to 50%, if amenable for pulmonary metastasectomy. Methods: Retrospective review of the two-year local control (LC), local-regional control (LRC) within the same lobe, OS, and toxicity rates in consecutive patients with metastatic pulmonary HNC who underwent stereotactic ablative radiotherapy (SABR) January 2007 to May 2018. Results: Evaluated 82 patients with 107 lung lesions, most commonly squamous cell carcinoma (SCC; 64%). Median follow-up was 20 months (range: 9.0-97.6). Systemic therapy administered in 34%. LC, LRC, and OS rates were 94%, 90%, and 62%. Patients with oligometastatic disease had a higher OS than polymetastatic disease, 72% vs 44% (HR = 0.30, 95% CI: 0.14-0.64; P =.008). OS in oligometastatic non-SCC and SCC were 100% and 66% (P =.03). There were no grade ≥3 toxicities. Conclusions: Metastatic pulmonary HNCs after SABR have a two-year OS rate comparable to pulmonary metastasectomy.

KW - oligometastasis

KW - pulmonary metastases

KW - pulmonary oligometastases

KW - squamous cell carcinoma

KW - stereotactic body radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85080936835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85080936835&partnerID=8YFLogxK

U2 - 10.1002/hed.26117

DO - 10.1002/hed.26117

M3 - Article

C2 - 32129548

AN - SCOPUS:85080936835

SN - 1043-3074

VL - 42

SP - 1939

EP - 1953

JO - Head and Neck

JF - Head and Neck

IS - 8

ER -

Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this